Avantex Biotechnologies Inc.
  • About
    • Overview
    • Management & Directors
    • Disclaimer
  • Applications
    • Lung Cancer Application
      • – Lung Cancer Problem
      • – Lung Cancer in China
    • Eye-Care Application
    • MRI Application
    • Cannabis Applications
    • Published Research Papers
  • News
    • Industry News
    • Media Contact
  • Contact
    • Contact Information
  • Search
  • Menu Menu

News

Industry News

Avantex Biotechnologies Inc. provides industry news relevant to our medical therapy and cannabis sectors that we work in.

Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

May 14, 2018/in In the News/by avantexb

PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the “Company”) and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2018-05-14 12:00:182018-12-11 08:38:15Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

Double-drug strategy blocks escape route for most lung cancers

April 3, 2018/in In the News/by avantexb

A one-two combo punch using two currently available drugs could be an effective treatment for the majority of lung cancers, a study shows. UT Southwestern Medical Center – A one-two combo punch using two currently available drugs could be an effective treatment for the majority of lung cancers, a study by scientists with UT Southwestern’s […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2018-04-03 12:00:442021-10-12 00:30:39Double-drug strategy blocks escape route for most lung cancers

Santen Pharmaceutical to Leverage Medidata Edge CTMS to Drive Future Growth in Ophthalmic Clinical Development

March 22, 2018/in In the News/by avantexb

Company adopts Edge CTMS in Japan as part of rapid global expansion February 20, 2018 08:30 AM Eastern Standard Time NEW YORK – (BUSINESS WIRE) – Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS (Clinical Trial Management System) to support its clinical trial operations, […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2018-03-22 12:00:242018-03-22 00:53:33Santen Pharmaceutical to Leverage Medidata Edge CTMS to Drive Future Growth in Ophthalmic Clinical Development

Dry Eye Disease Market, Punctal Plugs, and Secretagogue; Distribution Channel

March 13, 2018/in In the News/by avantexb

Hospital Pharmacies, Independent Pharmacies & Drug Stores, and Online pharmacies – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025 LONDON, March 13, 2018 /PRNewswire/ — Global Dry Eye Disease Market: Overview – News provided by ReportBuyer Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2018-03-13 12:00:162018-03-22 00:51:05Dry Eye Disease Market, Punctal Plugs, and Secretagogue; Distribution Channel

Roche Acquires Ignyta for US$1.7 Billion at US$27.00 Per Share

December 22, 2017/in In the News/by avantexb

SAN DIEGO – (BUSINESS WIRE) – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2017-12-22 12:00:232017-12-23 21:16:49Roche Acquires Ignyta for US$1.7 Billion at US$27.00 Per Share

Market Research: Global Lung Cancer Therapeutics Market to contribute around $11.19 billion during the period 2017-2020

June 13, 2017/in In the News/by avantexb

ResearchMoz presents professional and in-depth study of “Global Lung Cancer Therapeutics Market 2016-2020”. Published June 13, 2017 Medgadget, LLC. 2004-2016. All rights reserved. The Medical Revolution Will Be Blogged ResearchMoz presents professional and in-depth study of “Global Lung Cancer Therapeutics Market 2016-2020”. Lung cancer is a common cause of mortality and morbidity in both developed […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2017-06-13 10:00:352017-06-19 21:55:40Market Research: Global Lung Cancer Therapeutics Market to contribute around $11.19 billion during the period 2017-2020

World Lung Cancer Therapeutics Market – Opportunities and Forecasts, 2014 – 2022

May 10, 2017/in In the News/by avantexb

World Lung Cancer Therapeutics Market Opportunities and Forecasts 2014-2017 & 2022: Leading Companies are Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Co, Pfizer, and Agennix – Research and Markets Published by Research and Markets  Research and Markets has announced the addition of the “World Lung Cancer Therapeutics Market – Opportunities and Forecasts, 2014 – 2022” report […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2017-05-10 10:00:362017-06-19 23:33:53World Lung Cancer Therapeutics Market – Opportunities and Forecasts, 2014 – 2022

AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion

April 28, 2016/in In the News/by avantexb

Fortune | Finance | Dan Primack Published April 28, 2016 Pharma giant AbbVie Inc. this morning said it will acquire privately held cancer drug developer Stemcentrx in a blockbuster deal that could be worth up to $10.2 billion. Not only would that make this one of the largest biotech acquisitions in recent memory, but also […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2016-04-28 08:00:552017-06-26 07:29:46AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion

Attacking The Big C: Funding To Cancer Therapeutics Jumps To $2.8B In 2015

March 15, 2016/in In the News/by avantexb

Equity funding to private cancer therapeutics companies was up 153% in the year. The current quarter has already set a deal record. Published 2017 CB Insights Blog We recently highlighted how cancer drugs were an area of high interest for pharmaceutical corporates, with one fifth of their deals to private companies since 2013 going to cancer drugs and […]

Read more
http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png 0 0 avantexb http://avantexbio.com/wp-content/uploads/2017/05/avantext-bio-logo-Active-targeting-nano-particle-dual-drug-co-delivery-system-synergistic-anti-cancer-therapy-improved-cancer-therapeutics-2.png avantexb2016-03-15 08:00:202021-10-12 00:14:12Attacking The Big C: Funding To Cancer Therapeutics Jumps To $2.8B In 2015
Page 2 of 212

  • Industry News
  • Media Contact

INDUSTRY NEWS

  • Graphite Nanomaterials Reviewed for Role in Drug Delivery SystemsAugust 18, 2022 - 9:33 pm
  • Samsung invests $15 million in US biotech firm to develop core nanotechnology drug deliveryAugust 12, 2022 - 10:03 pm
  • Mesoporous silica nanoparticles: Possibilities in therapeutic developmentJuly 28, 2022 - 10:00 pm
  • How different cancer cells respond to drug-delivering nanoparticlesJuly 22, 2022 - 9:19 pm
  • What to Expect From the Launch of Cannabis Edibles in CanadaDecember 31, 2019 - 12:00 pm
  • New Cannabis Products to Follow Edibles LegalizationSeptember 5, 2019 - 12:00 pm

ABOUT
Overview
Management & Directors
Disclaimer

BIOTECH APPLICATIONS
Eye-Care Application
Lung Cancer Application
– Lung Cancer Problem
– Lung Cancer in China
Cannabis Applications
MRI Application
Research Papers

NEWS
Industry News
Media Contact

CONTACT
Contact Information

CONTACT
Nikita Chou, President
E: nchou@avantexbio.com
M: +1-778-888-3892

Ullrich Schade, VP Marketing
E: uschade@avantexbio.com
M: +1-604-644-4914

Branding by:
NextPhase Strategy

Scroll to top